New imaging tool is lighting up prostate cancer
Prostate cancer is the second most common cancer in men, with over 288,000 new cases diagnosed each year. It’s also one of the most curable cancers if detected early.
Source: news4jax.com
Davidm Schuster News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Davidm Schuster. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Davidm Schuster Today - Breaking & Trending Today
Health Beat: Lighting up prostate cancer
A new imaging tool is transforming the way doctors detect and manage prostate cancer.
Source: wfmz.com
U.S. FDA Approves Blue Earth Diagnostics' POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
POSLUMA will be commercially available in the United States in early June 2023
Source: itnonline.com
FDA Approves Imaging Agent With Radiohybrid Technology to Identify Location, Extent of Prostate Cancer
The radiohybrid imaging agent allowed positron emission tomography to identify prostate cancer with an 83% detection rate.
Source: pharmacytimes.com
U.S. FDA Approves Blue Earth Diagnostics' POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
- POSLUMA will be commercially available in the United States in early June 2023 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative
Source: finanznachrichten.de